Sign In
Buy NTLA
$13.02
-0.110 (-0.84%)
At Close: Jun 03, 2026
If You Invested $100 in CRISPR Therapeutics' IPO, This Is How Much Money You'd Have Now | The Motley Fool
12:10pm, Sunday, 26'th Jul 2020
A simple investment in CRISPR Therapeutics during its IPO four years ago would have netted investors nearly six times their investment today.
Gene Therapy Companies Are Racing to Cure Sickle Cell. That Would Open the Door to Curing Dozens of Other Diseases.
03:52pm, Saturday, 25'th Jul 2020
Successful treatments would demonstrate the potential for gene therapy—and boost a number of biotech companies.
Is CRISPR Therapeutics Stock a Buy? | The Motley Fool
10:45am, Saturday, 25'th Jul 2020
The gene-editing pioneer is a favorite among biotech investors and its stock is hitting new highs.
Gene Therapy Companies Are Racing to Cure Sickle Cell. That Would Open the Door to Curing Dozens of Other Diseases.
08:23pm, Friday, 24'th Jul 2020
Successful treatments would demonstrate the potential for gene therapy—and boost a number of biotech companies.
MeiraGTx Positive Data, And Other News: The Good, Bad And Ugly Of Biopharma
06:38pm, Monday, 20'th Jul 2020
MeiraGTx reports encouraging data for ocular gene therapy. Eli Lilly posts positive update for Mirikizumab.
Jose E. Rivera Sells 5,615 Shares of Intellia Therapeutics Inc (NASDAQ:NTLA) Stock
05:30am, Sunday, 19'th Jul 2020
Intellia Therapeutics Inc (NASDAQ:NTLA) EVP Jose E. Rivera sold 5,615 shares of Intellia Therapeutics stock in a transaction on Wednesday, July 15th. The shares were sold at an average price of $22.70
Wells Fargo & Company MN Purchases 18,857 Shares of Intellia Therapeutics Inc (NASDAQ:NTLA)
08:02am, Friday, 17'th Jul 2020
Wells Fargo & Company MN lifted its position in shares of Intellia Therapeutics Inc (NASDAQ:NTLA) by 30.5% in the first quarter, according to the company in its most recent 13F filing with the Securit
Is Intellia Therapeutics Stock a Buy?
11:07am, Tuesday, 14'th Jul 2020
Intellia Therapeutics (NASDAQ: NTLA) is a biotech company that focuses on gene editing, a relatively new technology that could allow scientists to devise therapies for otherwise impossible-to-treat co
The Daily Biotech Pulse: Ziopharm Starts Blood Cancer Study, Allergan's Botox Gets Label Expansion, 3 IPOs
12:00am, Friday, 10'th Jul 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 9)
Affimed NV (NASDAQ: AFMD)...
The Daily Biotech Pulse: FDA Nod For Osmotica, OptiNose Strikes Co-promotion Deal, Orphan Drug Designation For AnaptysBio
12:00am, Thursday, 09'th Jul 2020
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 8)
Akero Therapeutics Inc (...
6 Stocks That Could Pop Higher
12:00am, Wednesday, 08'th Jul 2020
Stocks Analysis by Harry Boxer covering: BioCryst Pharmaceuticals Inc, Cytokinetics Inc, Vaxart Inc, Novavax Inc. Read Harry Boxer's latest article on Investing.com
Intellia Therapeutics, Inc. (NTLA): Hedge Funds Taking Some Chips Off The Table
02:52am, Monday, 06'th Jul 2020
At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (see why hell is coming). In these volatile market
Intellia Therapeutics Inc (NASDAQ:NTLA) Shares Sold by Victory Capital Management Inc.
04:20am, Sunday, 05'th Jul 2020
Victory Capital Management Inc. reduced its stake in Intellia Therapeutics Inc (NASDAQ:NTLA) by 36.3% in the first quarter, according to the company in its most recent 13F filing with the Securities a
Better Buy: Editas Medicine vs. Intellia
03:32pm, Thursday, 02'nd Jul 2020
Which of these companies that are developing cutting-edge gene-editing technologies is the better buy for investors?
